Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3G623R Solvent-Front Mutation

Research output: Contribution to journalCase reportContributedpeer-review

Contributors

Details

Original languageEnglish
Pages (from-to)687-694
Number of pages8
JournalJCO precision oncology
Volume5
Publication statusPublished - Nov 2021
Peer-reviewedYes

External IDs

Scopus 85117736711
Mendeley 702ed7f2-03d4-3a82-a8ff-a7631ed2764e

Keywords